RxDoctor Payments Data

Miriam Lopez

Family · Houston, TXNPI 1144983313

Payments from drug & device makers

$822in general payments, 2019–2025

Across 44 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$307
  • Corium, LLC$72
  • Neurocrine Biosciences, Inc.$55
  • Takeda Pharmaceuticals U.S.A., Inc.$53
  • Sunovion Pharmaceuticals Inc.$50
  • Phadia US Inc.$46
  • plus $239 from 10 others

What the payments were for

  • Food & beverage$822100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$822 in reported general payments places this provider in the 65th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$18,599
Medicare patients
72
Services billed
867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin72$104,043
TrulicityDulaglutide38$60,697
EliquisApixaban36$52,851
FarxigaDapagliflozin Propanediol33$40,856
OzempicSemaglutide23$37,840
Soliqua 100-33Insulin Glargine/Lixisenatide41$34,852
XareltoRivaroxaban26$30,788
JanuviaSitagliptin Phosphate21$23,414
Icosapent Ethyl40$20,874
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,981
Tresiba Flextouch U-100Insulin Degludec16$9,487
Atorvastatin Calcium638$6,626
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$4,078
Omega-3 Acid Ethyl Esters22$3,849
Gabapentin105$3,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$52,85136 claims
AstraZenecaFarxiga$14$40,85633 claims
Novo NordiskOzempic$23$37,84023 claims
Johnson & JohnsonXarelto$45$30,78826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 15,456 family providers in Texas.

Other family in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →